Estados Unidos - inglés - NLM (National Library of Medicine)

photomedex, inc. - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w) -

Estados Unidos - inglés - NLM (National Library of Medicine)

photomedex, inc. - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) -

Estados Unidos - inglés - NLM (National Library of Medicine)

photomedex, inc. - avobenzone 3%, homosalate 7%, octisalate 5%, octocrylene, 6%. -

Estados Unidos - inglés - NLM (National Library of Medicine)

photomedex, inc. - octinoxate 7.5%, zinc oxide 9.0% - sunscreen - helps prevent sunburn - if used as directed and with other sun protection measures (see directions), decreases the risk of skin cancer and early skin again caused by the sun. do not use on damaged or broken skin. stop use and ask a doctor if rash occurs.

Estados Unidos - inglés - NLM (National Library of Medicine)

photomedex, inc. - octinoxate 3.0%, titanium dioxide 3.0%, zinc oxide 9.0% - sunscreen - helps prevent sunburn - if used as directed and with other sun protection measures (see directions) , decreases the risk of skin cancer and early skin again caused by the sun. do not use on damaged or broken skin. stop use and ask a doctor if rash occurs.

Estados Unidos - inglés - NLM (National Library of Medicine)

photomedex, inc. - octinoxate 6.5%, octisalate 2.5% zinc oxide 8.5% - sunscreen - helps prevent sunburn - if used as directed and with other sun protection measures (see directions), decreases the risk of skin cancer and early skin again caused by the sun. do not use on damaged or broken skin. stop use and ask a doctor if rash occurs.

Estados Unidos - inglés - NLM (National Library of Medicine)

photomedex, inc - homosalate (unii: v06sv4m95s) (homosalate - unii:v06sv4m95s), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox) - - helps prevent sunburn  - if used as directed with other sun protection measures (seedirections ), decreases the risk of skin cancer and early skin aging caused by the sun. directions  - apply liberally 15 minutes before sun exposure. - use a water resistant sunscreen if swimming or sweating - reapply at least every 2 hours - children under 6 months of age: ask a doctor - sun protection measures. spending time in the sun increases your risk of skin cancer and early skin aging.  to decrease this risk, regularly use a sunscreen with a broad spectrum spf of 15 or higher and other sun protection measures including -  limit time in the sun, especially from 10 a.m.- 2 p.m. - wear long-sleeve shirts, pants, hats and sunglasses.                                

Canadá - inglés - Health Canada

medexus pharmaceuticals inc. - aminolevulinic acid hydrochloride - powder for solution - 1.5g - aminolevulinic acid hydrochloride 1.5g - roentgenography

Australia - inglés - Department of Health (Therapeutic Goods Administration)

promedex pty ltd -

Estados Unidos - inglés - NLM (National Library of Medicine)

medexus pharma inc. - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 7.5 mg in 0.15 ml - rasuvo is indicated in the management of selected adults with severe, active rheumatoid arthritis (ra) (acr criteria), or children with active polyarticular juvenile idiopathic arthritis (pjia), who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (nsaids). rasuvo is indicated in adults for the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. it is important to ensure that a psoriasis "flare" is not due to an undiagnosed concomitant disease affecting immune responses. rasuvo is not indicated for the treatment of neoplastic diseases. rasuvo is contraindicated in the following: • pregnancy rasuvo can cause embryo-fetal toxicity and fetal death when administered during pregnancy. [see warnings and precautions (5.